vs
Side-by-side financial comparison of Dolby Laboratories, Inc. (DLB) and iRhythm Holdings, Inc. (IRTC). Click either name above to swap in a different company.
Dolby Laboratories, Inc. is the larger business by last-quarter revenue ($395.6M vs $208.9M, roughly 1.9× iRhythm Holdings, Inc.). Dolby Laboratories, Inc. runs the higher net margin — 24.0% vs 2.7%, a 21.3% gap on every dollar of revenue. On growth, iRhythm Holdings, Inc. posted the faster year-over-year revenue change (27.1% vs 7.1%). Over the past eight quarters, iRhythm Holdings, Inc.'s revenue compounded faster (25.8% CAGR vs 13.9%).
Dolby Laboratories, Inc. is an American technology corporation specializing in audio noise reduction, audio encoding/compression, spatial audio, and high-dynamic-range television (HDR) imaging. Dolby licenses its technologies to consumer electronics manufacturers.
iRhythm Holdings is a digital healthcare company focused on cardiac care, developing and commercializing wearable ambulatory heart monitoring devices paired with AI-powered analytical tools. It primarily serves healthcare providers and patients across the United States, helping to detect undiagnosed arrhythmias such as atrial fibrillation through convenient long-term heart rhythm tracking that delivers actionable clinical insights.
DLB vs IRTC — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $395.6M | $208.9M |
| Net Profit | $94.9M | $5.6M |
| Gross Margin | 88.7% | 70.9% |
| Operating Margin | 28.5% | 1.1% |
| Net Margin | 24.0% | 2.7% |
| Revenue YoY | 7.1% | 27.1% |
| Net Profit YoY | 3.4% | 518.5% |
| EPS (diluted) | $0.99 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | $395.6M | — | ||
| Q1 26 | $346.7M | — | ||
| Q4 25 | $346.7M | $208.9M | ||
| Q3 25 | $307.0M | $192.9M | ||
| Q2 25 | $315.5M | $186.7M | ||
| Q1 25 | $369.6M | $158.7M | ||
| Q4 24 | $357.0M | $164.3M | ||
| Q3 24 | $304.8M | $147.5M |
| Q2 26 | $94.9M | — | ||
| Q1 26 | $53.3M | — | ||
| Q4 25 | $53.3M | $5.6M | ||
| Q3 25 | $49.3M | $-5.2M | ||
| Q2 25 | $46.1M | $-14.2M | ||
| Q1 25 | $91.8M | $-30.7M | ||
| Q4 24 | $67.8M | $-1.3M | ||
| Q3 24 | $58.6M | $-46.2M |
| Q2 26 | 88.7% | — | ||
| Q1 26 | 87.5% | — | ||
| Q4 25 | 87.5% | 70.9% | ||
| Q3 25 | 87.1% | 71.1% | ||
| Q2 25 | 86.1% | 71.2% | ||
| Q1 25 | 90.3% | 68.8% | ||
| Q4 24 | 88.6% | 70.0% | ||
| Q3 24 | 88.8% | 68.8% |
| Q2 26 | 28.5% | — | ||
| Q1 26 | 17.9% | — | ||
| Q4 25 | 17.9% | 1.1% | ||
| Q3 25 | 9.7% | -4.4% | ||
| Q2 25 | 15.1% | -10.0% | ||
| Q1 25 | 29.2% | -20.5% | ||
| Q4 24 | 22.4% | -2.5% | ||
| Q3 24 | 15.2% | -34.1% |
| Q2 26 | 24.0% | — | ||
| Q1 26 | 15.4% | — | ||
| Q4 25 | 15.4% | 2.7% | ||
| Q3 25 | 16.1% | -2.7% | ||
| Q2 25 | 14.6% | -7.6% | ||
| Q1 25 | 24.8% | -19.3% | ||
| Q4 24 | 19.0% | -0.8% | ||
| Q3 24 | 19.2% | -31.3% |
| Q2 26 | $0.99 | — | ||
| Q1 26 | $0.55 | — | ||
| Q4 25 | $0.55 | $0.18 | ||
| Q3 25 | $0.50 | $-0.16 | ||
| Q2 25 | $0.48 | $-0.44 | ||
| Q1 25 | $0.94 | $-0.97 | ||
| Q4 24 | $0.70 | $-0.03 | ||
| Q3 24 | $0.59 | $-1.48 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $594.7M | $583.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.6B | $152.7M |
| Total Assets | $3.2B | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | $594.7M | — | ||
| Q1 26 | $644.6M | — | ||
| Q4 25 | $644.6M | $583.8M | ||
| Q3 25 | $702.6M | $565.2M | ||
| Q2 25 | $699.3M | $545.5M | ||
| Q1 25 | $626.6M | $520.6M | ||
| Q4 24 | $520.8M | $535.6M | ||
| Q3 24 | $482.0M | $522.0M |
| Q2 26 | $2.6B | — | ||
| Q1 26 | $2.6B | — | ||
| Q4 25 | $2.6B | $152.7M | ||
| Q3 25 | $2.6B | $121.9M | ||
| Q2 25 | $2.6B | $103.7M | ||
| Q1 25 | $2.6B | $86.7M | ||
| Q4 24 | $2.5B | $90.9M | ||
| Q3 24 | $2.5B | $71.8M |
| Q2 26 | $3.2B | — | ||
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.2B | $1.0B | ||
| Q3 25 | $3.2B | $995.2M | ||
| Q2 25 | $3.2B | $964.0M | ||
| Q1 25 | $3.2B | $926.1M | ||
| Q4 24 | $3.2B | $931.4M | ||
| Q3 24 | $3.1B | $909.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $147.3M | $26.2M |
| Free Cash FlowOCF − Capex | — | $14.5M |
| FCF MarginFCF / Revenue | — | 6.9% |
| Capex IntensityCapex / Revenue | — | 5.6% |
| Cash ConversionOCF / Net Profit | 1.55× | 4.70× |
| TTM Free Cash FlowTrailing 4 quarters | — | $34.5M |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | $147.3M | — | ||
| Q1 26 | $54.8M | — | ||
| Q4 25 | $54.8M | $26.2M | ||
| Q3 25 | $472.2M | $34.9M | ||
| Q2 25 | $67.7M | $27.7M | ||
| Q1 25 | $174.9M | $-7.9M | ||
| Q4 24 | $106.8M | $19.2M | ||
| Q3 24 | $327.3M | $24.3M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $50.2M | $14.5M | ||
| Q3 25 | $435.9M | $20.1M | ||
| Q2 25 | $61.3M | $17.3M | ||
| Q1 25 | $168.0M | $-17.3M | ||
| Q4 24 | $100.0M | $12.4M | ||
| Q3 24 | $297.2M | $15.5M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 14.5% | 6.9% | ||
| Q3 25 | 142.0% | 10.4% | ||
| Q2 25 | 19.4% | 9.3% | ||
| Q1 25 | 45.5% | -10.9% | ||
| Q4 24 | 28.0% | 7.5% | ||
| Q3 24 | 97.5% | 10.5% |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 1.3% | 5.6% | ||
| Q3 25 | 11.8% | 7.7% | ||
| Q2 25 | 2.0% | 5.6% | ||
| Q1 25 | 1.9% | 5.9% | ||
| Q4 24 | 1.9% | 4.2% | ||
| Q3 24 | 9.8% | 6.0% |
| Q2 26 | 1.55× | — | ||
| Q1 26 | 1.03× | — | ||
| Q4 25 | 1.03× | 4.70× | ||
| Q3 25 | 9.57× | — | ||
| Q2 25 | 1.47× | — | ||
| Q1 25 | 1.91× | — | ||
| Q4 24 | 1.57× | — | ||
| Q3 24 | 5.59× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DLB
| Licensing | $372.2M | 94% |
| Products and services | $23.4M | 6% |
IRTC
| Commercial Payors | $111.7M | 53% |
| Centers For Medicare And Medicaid | $49.2M | 24% |
| Healthcare Institutions | $34.3M | 16% |
| Non Contracted Third Party Payors | $13.7M | 7% |
